On behalf of the Working Group of the BioRegions of Germany (AK-BioRegions), the BioRN Life Science Cluster Rhein-Neckar would like to invite you to the virtual presentation of the EY Biotech Report on Tuesday, 13.07.2021 at 3 pm.
During the pandemic, the innovative strength of German biotech companies in particular has become impressively visible. It turned out that this industry can show the way out of the crisis through tests, diagnostics, therapies and vaccines. Biotechnology has thus become the focus of attention – in society, politics, the media and investors. In many areas, the sector has been able to develop a new dynamic and set records in financing, turnover, number of employees and expenditure on research & development. Biotechnology is thus at a turning point, at a “tipping point”, as described in EY’s German Biotechnology Report 2021. The central question is: in which direction is the sector developing after the pandemic? The report provides answers to these questions. It shows what opportunities now arise, what new challenges arise and what needs to be done to use the momentum in the long term.
Program, moderated by Julia Schaft, Managing Director, BioRN:
- Welcome on behalf of the AK BioRegio – André Hofmann (CEO, biosaxony e. V.)
- Presentation of the EY-Report – Alexander W. Nuyken (Head of Life Sciences Strategy and Transactions EMEIA)
- SprinD-Challenge: Leap innovations to fight viral infections – Jano Costard (Challenge Officer, SprinD)
- Adoption (vorr. 4:30 pm)
We kindly ask you to register free of charge via this link. You will receive the access data shortly before the event.